AI Article Synopsis
- Bone marrow-derived mesenchymal stem cells (BMSCs) are being researched for their potential in treating immune and tissue repair issues, but they struggle to reach damaged areas effectively.
- A specific pathway involving stromal cell-derived factor 1 (SDF-1) and its receptor CXCR4 is crucial for helping BMSCs migrate to these areas.
- This study successfully modified BMSCs by enhancing both CXCR4 and the cytokine interleukin 35 (IL-35), leading to improved movement and immune regulation, indicating a promising new approach for treating autoimmune diseases.
Article Abstract
Bone marrow-derived mesenchymal stem cells (BMSCs) have been widely studied for their applications in immunoregulation and tissue repair. However, the therapeutic effects of BMSCs in the body are limited, partly due to the low homing efficiency of BMSCs to affected parts. The stromal cell-derived factor 1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR4) axis is well known to play an essential role in the homing of BMSCs. Interleukin 35 (IL-35) is a newly discovered cytokine confirmed to inhibit overactivated immune function and have a good therapeutic effect on autoimmune diseases. In this study, we innovatively developed dual gene modification of BMSCs by transducing CXCR4 and IL-35 and found that the migration and immunomodulatory activity of genetically engineered BMSCs were significantly enhanced compared to their natural counterparts. These results suggest that BMSCs modified by dual overexpression of CXCR4 and IL-35 may provide a potential treatment strategy for autoimmune diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.molimm.2022.07.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!